KOSDAQBiotech & Pharma287840

IntoCell

₩11,300▼ 2.25%2026-11-18 close
Market Cap
₩169.7B
Turnover
₩200M
Volume
20K
Shares out.
15M
PER
—
PBR
10.0×
EPS
-₩784
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

IntoCell: ADC Licensing Push Amid Persistent Losses

IntoCell is widening its ADC business from platform licensing to pipeline licensing, but it has reported losses for three consecutive years and operating losses in each of the last five quarters.

  1. 1

    Revenue peaked at KRW 2.91 billion in 2024, fell to KRW 2.3 billion in 2025, and was KRW 53.91 million in the third quarter of 2026.

  2. 2

    The operating loss widened to KRW 3.6 billion in the third quarter of 2026, from KRW 1.3 billion a year earlier.

  3. 3

    A definitive agreement for the Nectin-4 ADC candidate SBE303 with Samsung Bioepis was signed in July 2026, and the candidate is in a global Phase 1 trial.

  4. 4

    The company expects interim data from ITC-6146RO, a B7-H3-targeted candidate in Phase 1a, around year-end 2026, and plans to add five pipeline targets within 2026 to reach ten.

  5. 5

    IntoCell was designated an investment-caution stock on August 5, 2026, and is responding to the patent dispute over Nexatecan that surfaced in July 2025 with follow-on payloads.

02

Business structure

IntoCell was founded in 2015 and operates an antibody-drug conjugate (ADC) platform. Its core technology is the in-house OHPAS linker that connects antibodies to payloads, and it holds or develops a Nexatecan payload family of about 30 compounds along with Duocarmycin-based payloads.

Its main revenue source is technology licensing (L/O) of the linker platform, so revenue depends heavily on when licensing income is recognized. The business model is shifting from platform licensing toward pipeline-candidate licensing.

Its own pipeline consists of ITC-6146RO, a B7-H3-targeted candidate in Phase 1a at three large hospitals in Korea, and a 5T4-targeted ADC in preclinical development.

In its partnership with Samsung Bioepis, a 2023 research agreement covering up to five targets led to a definitive agreement for SBE303, a Nectin-4-targeted ADC, in July 2026. According to the company, overseas firms including three in the US and one in the UK are testing its technology.

IntoCell has also signed strategic agreements with global CMO companies to add its linker-payload combinations to their ADC toolbox.

In terms of competition, the company cites LigaChem Biosciences, which licenses both platforms and pipeline assets, as its growth model, while ABL Bio terminated a platform licensing contract with IntoCell after the patent dispute.

The company targets reaching Stage 3 of new drug development by 2030 and says it is about two-thirds of the way to Stage 2.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.4B-₩1.3B−91.3%
2025Q4₩700M-₩1.9B−256.8%
2026Q1₩300M-₩3.5B−1255.8%
2026Q2₩800M-₩2.2B−290.2%
2026Q3₩53,909,034-₩3.6B−6678.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩1.6B-₩17.4B-₩16.8B−1075.8%−126.8%96.1%
2024₩2.9B-₩9.8B-₩9.9B−337.0%−131.8%215.2%
2025₩2.3B-₩10.3B-₩10.6B−448.0%−42.8%66.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed annual basis, revenue rose from KRW 1.62 billion in 2023 to KRW 2.91 billion in 2024, a 79.7% increase, and then fell to KRW 2.3 billion in 2025, a 20.9% decline. Among 2023 to 2025, 2024 was the largest year and 2023 was the smallest.

The operating loss was KRW 17.4 billion in 2023, KRW 9.79 billion in 2024 and KRW 10.3 billion in 2025, so the company has posted operating losses for three consecutive years, with the loss narrowing in 2024 and widening again in 2025.

The operating margin was -1,075.8% in 2023, -337.0% in 2024 and -448.0% in 2025, which shows that the loss burden remains large relative to revenue.

The net loss attributable to controlling shareholders was KRW 16.8 billion in 2023, KRW 9.91 billion in 2024 and KRW 10.6 billion in 2025, and the net loss including non-controlling interests was reported at the same levels.

In its February 2026 disclosure, the company cited missed targets for additional technology commercialization contracts and a deferral of revenue recognition on amounts already received as reasons for the 2025 revenue decline.

Quarterly revenue was KRW 1.42 billion in the third quarter of 2025, KRW 728 million in the fourth quarter, KRW 281 million in the first quarter of 2026, KRW 760 million in the second quarter and KRW 53.91 million in the third quarter, a pattern that moves sharply with the timing of licensing revenue.

The operating loss went from KRW 1.3 billion in the third quarter of 2025 to KRW 1.87 billion in the fourth quarter and KRW 3.53 billion in the first quarter of 2026, narrowed to KRW 2.21 billion in the second quarter, and widened again to KRW 3.6 billion in the third quarter.

Net losses attributable to controlling shareholders have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the total for the latest four quarters is KRW 11.8 billion.

Operating cash flow was -KRW 16.8 billion in 2023, -KRW 7.05 billion in 2024 and -KRW 8.63 billion in 2025, indicating continued cash outflows.

At the end of 2025, total equity was KRW 24.7 billion, all attributable to controlling shareholders, total liabilities were KRW 16.5 billion, and the debt ratio fell from 215.2% in 2024 to 66.7% in 2025.

05

Industry analysis

Industry commentary suggests that competition in ADCs is shifting from individual candidates toward the ability to combine linkers and payloads. A industry source noted that partners benefit more from the more technology combinations they can choose from by target.

The company believes that global large pharmaceutical firms are moving toward pipeline assets with preclinical and clinical data rather than platform technology alone.

Based on that view, IntoCell has described a path from platform sales to joint pipeline licensing, as LigaChem Biosciences has done, and then to its own drugs. The most direct domestic comparison the company points to is LigaChem Biosciences, another ADC platform company.

The company says that apart from the GGFG linker used in Enhertu, there is practically no linker that can conjugate neutral-group payloads, and it presents its TBA linker as a differentiator.

The Samsung Bioepis collaboration started with a December 2023 agreement covering up to five targets, and SBE303 became the first definitive agreement under it.

Independent data on market share or on licensing deal sizes relative to peers is not available beyond the company's own statements, so the company's position rests on those statements. Its standing will be tested by licensing results such as the number of deals, upfront payments and milestone terms.

06

Outlook

The company plans to add five new pipeline targets within 2026, which would bring its own pipeline from five to ten. Two of these targets have been identified, and the remaining three are under review.

ITC-6146RO, a B7-H3-targeted candidate, is in Phase 1a at three large hospitals in Korea, and the company expects to see interim data around year-end. The 5T4 ADC has entered preclinical development, and the DLL3 ADC is targeted to enter preclinical development in 2027.

SBE303 is in a global Phase 1 trial enrolling 149 patients with solid tumors, and the agreement includes development-stage milestones as well as post-commercialization sales milestones and royalties. The total contract value and detailed terms have not been disclosed, as agreed by both parties.

The company says its TBA linker is nearing completion, and it intends to use it to widen the range of conjugatable drugs, including neutral-group payloads. The company has set a target of ten technology exports by 2028 and a medium-term goal of reaching Stage 3 of new drug development by 2030.

The next regular report is the 2026 annual report, and its disclosure of full-year revenue, operating loss and cash flows will clarify the scale and timing of licensing income.

07

Valuation

PER
—
PBR
10.0×
ROE
-58.0%
EPS
-₩784
BPS
₩1,164
Dividend per share
₩0

Because the company has been loss-making over the latest four quarters, a PER cannot be calculated on an earnings basis. The price-to-book ratio sits in a high premium range relative to book equity, so the share price reflects expectations for future licensing income well above the value of net assets.

Comparing total equity of KRW 24.7 billion at the end of 2025 with the KRW 11.8 billion net loss attributable to controlling shareholders over the latest four quarters shows that the speed at which losses erode equity is a key variable in interpreting valuation.

Because the company is loss-making, its dividend yield is below the industry average. A historical PER band is hard to use as a benchmark because earnings have been negative, and comparisons with listed peers are limited by large differences in revenue scale.

In practice, multiple interpretation depends less on current earnings and more on future revenue assumptions such as pipeline deal values, milestones and clinical data.

The deal value and stage of licensing agreements and the quarterly operating loss trend are the factual drivers that would change how the multiples are read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Platform expansion with new payload and linker

The company said an ADC using its new payload iso-Nexatecan showed at least four times greater tumor suppression than Enhertu at the same dose in in vivo efficacy tests. These tests were run by an outside CRO and are not human data, so they should be read as company statements.

The TBA linker extends conjugation to neutral-group payloads, including alcohol-group drugs, and is presented as expanding the combinations partners can choose by target.

SBE303 definitive agreement confirms licensing structure

Samsung Bioepis signed a follow-on R&D and commercialization agreement for SBE303, a Nectin-4-targeted ADC candidate, in July 2026. Kim Sun-ah, an analyst at Hana Securities, said the deal confirmed that IntoCell's platform technology can lead to an actual licensing structure.

The agreement includes payments after Phase 1 initiation, development and approval milestones, and sales royalties, but the total value has not been disclosed.

Pipeline growth and year-end interim data

The company plans to add five new targets within 2026, bringing its own pipeline to ten, and two of them have already been identified.

Interim data from the Phase 1a trial of ITC-6146RO is expected around year-end 2026, and the company says this could address the lack of human clinical data that it has called its biggest weakness.

The company says it aims to change its revenue model toward licensing pipeline assets alongside platforms, as LigaChem Biosciences does.

09

Bear factors

Three years of losses and wider quarterly losses

The operating loss persisted for three years, at KRW 17.4 billion in 2023, KRW 9.79 billion in 2024 and KRW 10.3 billion in 2025. The third-quarter 2026 operating loss of KRW 3.6 billion is wider than the KRW 1.3 billion in the third quarter of 2025.

Net losses attributable to controlling shareholders over the latest four quarters total KRW 11.8 billion, and operating cash outflow was -KRW 8.63 billion in 2025.

Dependence on licensing and revenue volatility

The company attributed the 2025 revenue decline to missed targets for additional commercialization contracts and to deferred revenue recognition. Third-quarter 2026 revenue was KRW 53.91 million, down 96.2% from KRW 1.42 billion a year earlier.

The company also said that talks with some customers that were underway around its listing stopped at the final signing stage because of the other party's circumstances, which shows the timing uncertainty of deals.

Patent dispute and investment-caution designation

In July 2025, IntoCell said its patent review found that an intermediate of a Chinese company's earlier patent had the same structure as one of its Nexatecan-family drugs. ABL Bio then terminated its platform licensing contract, and the share price fell.

On August 5, 2026, the company was designated an investment-caution stock after the top ten accounts accounted for 44.99% of buying.

10

Risk factors

Clinical and development risk

Most of the pipeline is at an early stage. ITC-6146RO is in Phase 1a, 5T4 is preclinical, and the DLL3, HER3 and PSMA programs are in development or preparing to enter preclinical work.

Because the company has described the lack of human clinical data as its biggest weakness, the year-end interim data could change the terms of pipeline licensing talks.

Patent and legal risk

Nexatecan 3 (NxT3) overlapped with an earlier patent held by a Chinese company, and the company is responding with the follow-on payload NxT32 and iso-Nexatecan. The company says the 18-month non-disclosure period for patent applications made it hard to check earlier patents in advance.

The patent issue has also been cited as a cause of delays in further licensing, and the new payloads will need to pass the same kind of review.

Financial structure and trading risk

At the end of 2025, total equity was KRW 24.7 billion and total liabilities were KRW 16.5 billion. Operating cash outflows have continued for three consecutive years, from 2023 to 2025, so the timing of upfront licensing payments could significantly change the cash position.

The August 2026 investment-caution designation resulted from concentrated trading by a small number of accounts and is not directly tied to the company's reported results.

11

What to watch next

  1. Year-end 2026

    Whether interim Phase 1a data for ITC-6146RO is released. These would be the first human data for the B7-H3 pipeline and would form the basis for later pipeline licensing talks.

  2. By December 31, 2026

    Whether five new pipeline targets are added to reach ten. The company says two are identified and three are under review, so the extent of target disclosure matters.

  3. Late March 2027

    Filing of the 2026 annual report. Full-year revenue, operating loss and operating cash flow will be updated, showing how much licensing income was recognized for the year.

  4. 2027

    Whether the DLL3 ADC enters preclinical development as targeted. This shows whether the pipeline expansion translates into actual development progress.

  5. 2028

    Progress toward the target of ten technology exports, a goal the company stated in a March 2026 interview. It can be checked through deal count and upfront payment size.

12

Overall view

IntoCell is in the process of widening its revenue model from platform licensing to pipeline licensing.

On a disclosed basis, it recorded operating and net losses for three consecutive years from 2023 to 2025, and net losses attributable to controlling shareholders for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Revenue fell from KRW 2.91 billion in 2024 to KRW 2.3 billion in 2025 and was KRW 53.91 million in the third quarter of 2026. On the other hand, the July 2026 definitive agreement for SBE303 with Samsung Bioepis confirmed that its platform technology is leading to an actual licensing structure.

The next checkpoints are the year-end interim data for ITC-6146RO and the addition of five new pipeline targets within 2026. The patent dispute and the August 2026 investment-caution designation remain factors to monitor for market confidence.

The 2026 annual report will update full-year revenue, operating loss and cash flows and will clarify the scale and timing of licensing income.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. butler.works
  2. comp.fnguide.com
  3. markets.hankyung.com
  4. m.thinkpool.com
  5. vegannews.co.kr
  6. m.news.nate.com
  7. biztop.co.kr
  8. fnnews.com
  9. news.nate.com
  10. news.bizwatch.co.kr
  11. medigatenews.com
  12. wowtv.co.kr
  13. news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. topstarnews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis